To explore advancements in precision medicine for myelofibrosis (MF) through an integrated approach considering biological and clinical factors.
Approach:
Integrated Assessment: Focus on marrow morphology, molecular profile, cytogenetics, clinical phenotype, symptom burden, and transplant fitness.
Differentiation of MF Types: Distinguish between primary MF and secondary MF arising from polycythemia vera or essential thrombocythemia.
Precision Care Implementation: Actionable strategies in diagnosis, risk assessment, JAK inhibitor selection, symptom assessment, and transplant timing.
AI Applications: Emerging AI tools in digital pathology and prognostic modeling require validation and oversight.
Key Findings:
Myelofibrosis is biologically heterogeneous, affecting treatment approaches.
Ruxolitinib is the first-line treatment for symptomatic disease; alternatives exist based on patient profiles.
Allogeneic hematopoietic cell transplantation is the only curative option and should be considered early for high-risk patients.
Interpretation:
Current precision medicine in MF emphasizes the importance of integrating biological and clinical data for tailored treatment strategies.
Limitations:
Many prognostic tools are primarily validated in primary MF cohorts, limiting their applicability to secondary MF.
AI applications in precision medicine require further validation and governance before routine use.
Conclusion:
The review highlights the need for a tailored approach in managing myelofibrosis, focusing on individual patient biology and treatment response.
An updated clinical practice guideline from the American Society for Radiation Oncology substantially expands and modernizes recommendations for the use of radiation therapy in pancreatic cancer.
